Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria

被引：0

作者：

Maurer, Marcus ^{[1
]}

Metz, Martin ^{[1
]}

Anderson, John ^{[2
,3
]}

Talreja, Neetu ^{[4
]}

Windom, Hugh ^{[5
,6
]}

Alvarado, Diego ^{[7
]}

Crowley, Elizabeth ^{[7
]}

Young, Diane ^{[7
]}

Merchant, Kunal ^{[7
]}

Paradise, Elsa ^{[7
]}

Heath-Chiozzi, Margo ^{[7
]}

Bernstein, Jonathan ^{[8
,9
]}

机构：

[1] Charite Univ Med Berlin, Berlin, Germany

[2] Univ Alabama Birmingham, Birmingham, AL USA

[3] AlIerVie Hlth, Birmingham, AL USA

[4] Allergy Grp & Treasure Valley Med Res, Boise, ID USA

[5] Univ S Florida, Sarasota, FL USA

[6] Windom Allergy Asthma Sinus, Sarasota, FL USA

[7] Celldex Therapeut, Hampton, NJ USA

[8] Univ Cincinnati, Cincinnati, OH USA

[9] Bernstein Allergy Grp Clin Res Ctr, Cincinnati, OH USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2023年 / 151卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

410

引用

页码：AB133 / AB133

页数：1

共 50 条

[1] Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria
Terhorst-Molawi, Dorothea
Hawro, Tomasz
Grekowitz, Eva
Kiefer, Lea
Merchant, Kunal
Alvarado, Diego
Thomas, Lawrence J.
Hawthorne, Thomas
Crowley, Elizabeth
Heath-Chiozzi, Margo
Metz, Martin
Maurer, Marcus
ALLERGY, 2023, 78 (05) : 1269 - 1279
[2] Open-label study on the efficacy of the anti-KIT antibody barzolvolimab in inducible urticaria
Brehler, R.
ALLERGOLOGIE, 2025, 48 (02)
[3] Barzolvolimab demonstrates clinical activity in a multiple ascending dose trial in chronic spontaneous urticaria
Maurer, M.
Metz, M.
Anderson, J.
Talreja, N.
Windom, H.
Alvarado, D.
Crowley, E.
Young, D.
Merchant, K.
Hawthorne, T.
Paradise, E.
Heath-Chiozzi, M.
Bernstein, J.
ALLERGY, 2023, 78 : 220 - 221
[4] Depletion of mast cells with barzolvolimab, an anti-KIT antibody, does not affect mast cell progenitor numbers or function
Monino-Romero, S.
Mahnke, N. A.
Gutsche, A.
Terhorst-Molawi, D.
Grekowitz, E. M.
Kiefer, L. A.
Alvarado, D.
Metz, M.
Siebenhaar, F.
Scheffel, J.
Maurer, M.
EXPERIMENTAL DERMATOLOGY, 2024, 33 (03)
[5] Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Spontaneous Urticaria: 52-Week Data
Maurer, Marcus
Metz, Martin
Kobielusz-Gembala, Iwona
Mitha, Essack
Leflein, Jeffrey
Gotua, Maia
Fuentes-Duculan, Judilyn
Paradise, Elsa
Ma, Rick
Green-berg, Steven
Young, Diane
Bernstein, Jonathan
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (02) : AB431 - AB431
[6] The Anti-KIT Antibody, CDX-0159, Reduces Mast Cell Numbers and Circulating Tryptase and Improves Disease Control in Patients with Chronic Inducible Urticaria (Cindu)
Terhorst-Molawi, Dorothea
Hawro, Tomasz
Grekowitz, Eva
Kiefer, Lea
Metz, Martin
Alvarado, Diego
Hawthorne, Thomas
Merchant, Kunal
Crew, Linda
Crowley, Elizabeth
Heath-Chiozzi, Margo
Maurer, Marcus
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB178 - AB178
[7] Safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria
Maurer, M.
Rosen, K.
Hsieh, H.
Blogg, M.
Georgiou, P.
Braeutigam, M.
Saini, S.
ALLERGY, 2012, 67 : 497 - 498
[8] Safety of omalizumab in elderly patients with chronic spontaneous urticaria
Narvaez Fernandez, E. J.
Mir Ihara, P. K.
Caballero Molina, T.
Dominguez-Ortega, J.
Cabanas Moreno, R.
Entrala Bueso, A.
ALLERGY, 2021, 76 : 234 - 234
[9] CLINICAL ACTIVITY OF AK002, AN ANTI-SIGLEC-8 ANTIBODY, IN MULTIPLE FORMS OF UNCONTROLLED CHRONIC URTICARIA
Altrichter, S.
Staubach, P.
Pasha, M.
Rasmussen, H.
Singh, B.
Chang, A.
Kamboj, A.
Bernstein, J.
Siebenhaar, F.
Maurer, M.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S27 - S28
[10] Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria
Skander, D.
Allenova, A.
Maurer, M.
Kolkhir, P.
EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 53 (02) : 91 - 93

← 1 2 3 4 5 →